BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30069578)

  • 1. Prognostic value of posttreatment
    Lima GM; Matti A; Vara G; Dondi G; Naselli N; De Crescenzo EM; Morganti AG; Perrone AM; De Iaco P; Nanni C; Fanti S
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2139-2146. PubMed ID: 30069578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer.
    Leseur J; Roman-Jimenez G; Devillers A; Ospina-Arango JD; Williaume D; Castelli J; Terve P; Lavoue V; Garin E; Lejeune F; Acosta O; De Crevoisier R
    Radiother Oncol; 2016 Sep; 120(3):512-518. PubMed ID: 27569847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET/CT Response Criteria (European Organization for Research and Treatment of Cancer) Predict Survival Better Than Response Evaluation Criteria in Solid Tumors in Locally Advanced Cervical Cancer Treated With Chemoradiation.
    Yoon JW; Kim S; Kim SW; Kim YT; Kang WJ; Nam EJ
    Clin Nucl Med; 2016 Sep; 41(9):677-82. PubMed ID: 27276204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of
    Rufini V; Collarino A; Calcagni ML; Meduri GM; Fuoco V; Pasciuto T; Testa AC; Ferrandina G; Gambacorta MA; Campitelli M; Gui B; Zannoni G; Manfredi R; Scambia G; Giordano A
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1228-1238. PubMed ID: 31414206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
    Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of FDG PET metabolic tumour volume versus ADC histogram: prognostic value of tumour treatment response and survival in patients with locally advanced uterine cervical cancer.
    Ueno Y; Lisbona R; Tamada T; Alaref A; Sugimura K; Reinhold C
    Br J Radiol; 2017 Jul; 90(1075):20170035. PubMed ID: 28508679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic parameters of [
    Markus M; Sartor H; Bjurberg M; Trägårdh E
    Acta Oncol; 2023 Feb; 62(2):180-188. PubMed ID: 36815676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Pretreatment Metabolic PET Parameters in Cervical Cancer Patients With Metabolic Complete Response After Concurrent Chemoradiotherapy.
    Son SH; Jeong SY; Chong GO; Lee YH; Park SH; Lee CH; Hong CM; Jeong JH; Lee SW; Ahn BC; Lee J
    Clin Nucl Med; 2018 Sep; 43(9):e296-e303. PubMed ID: 30036243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the prognostic value of F-18 FDG PET/CT metabolic parameters of primary tumors and MRI findings in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
    Dag Z; Yilmaz B; Dogan AK; Aksan DU; Ozkurt H; Kızılkaya HO; Arslan D
    Brachytherapy; 2019; 18(2):154-162. PubMed ID: 30594422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?
    Voglimacci M; Gabiache E; Lusque A; Ferron G; Ducassou A; Querleu D; Motton S; Chantalat E; Courbon F; Martinez A
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1551-1559. PubMed ID: 30729273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of metabolic parameters and textural analysis in predicting prognosis in locally advanced cervical cancer treated with chemoradiotherapy.
    Pedraza S; Seiffert AP; Sarandeses P; Muñoz-Lopez B; Gómez EJ; Sánchez-González P; Pérez-Regadera JF
    Strahlenther Onkol; 2022 Sep; 198(9):792-801. PubMed ID: 35072751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy.
    Vojtíšek R; Baxa J; Kovářová P; Almortaza A; Hošek P; Sukovská E; Tupý R; Ferda J; Fínek J
    Strahlenther Onkol; 2021 Jun; 197(6):494-504. PubMed ID: 33492444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of qualitative response assessment interpretation criteria at 18F-FDG PET-CT for predicting outcome in locally advanced cervical carcinoma treated with chemoradiotherapy.
    Scarsbrook A; Vaidyanathan S; Chowdhury F; Swift S; Cooper R; Patel C
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):581-588. PubMed ID: 27738729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of total lesion glycolysis measured by 18F-FDG PET/CT in patients with locally advanced cervical cancer.
    Hong JH; Jung US; Min KJ; Lee JK; Kim S; Eo JS
    Nucl Med Commun; 2016 Aug; 37(8):843-8. PubMed ID: 27058362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy.
    Choi HJ; Lee JW; Kang B; Song SY; Lee JD; Lee JH
    Yonsei Med J; 2014 Nov; 55(6):1498-506. PubMed ID: 25323885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive recurrence value of MTV-s as an 18F-FDG PET/CT index in patients with IIB-IVA cervical cancer.
    Deng C; Ding D; Wang M
    Postgrad Med; 2021 May; 133(4):436-443. PubMed ID: 33620285
    [No Abstract]   [Full Text] [Related]  

  • 17. The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma.
    Sun Y; Lu P; Yu L
    Acad Radiol; 2016 May; 23(5):605-10. PubMed ID: 26853968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic utility of serial
    Fernando S; Lin M; Pham TT; Chong S; Ip E; Wong K; Chua W; Ng W; Lin P; Lim S
    Br J Radiol; 2020 Jan; 93(1105):20190455. PubMed ID: 31617737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Texture analysis of
    Nakajo M; Jinguji M; Nakabeppu Y; Nakajo M; Higashi R; Fukukura Y; Sasaki K; Uchikado Y; Natsugoe S; Yoshiura T
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):206-214. PubMed ID: 27613542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.